We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agenus (AGEN) Reports Narrower-than-Expected Q1 Loss
Read MoreHide Full Article
Agenus Inc.(AGEN - Free Report) is a Lexington, MA-based development-stage company focused on the discovery and development of checkpoint modulators, vaccines and adjuvants for the treatment of cancer.
The company earns revenues primarily through fees received under collaboration and license agreements, which not only provide it with funds in the form of upfront and milestone payments and future royalties, but also validate the company’s proprietary product platform. In Mar 2017, the company undertook certain restructuring activities in order to cut costs and focus on developing key product candidates.
With no approved product in its portfolio yet, investor focus should remain on pipeline updates by the company. The company has three platform technologies for the development of its candidates – Retrocyte Display, SECANT and phage display – each designed to produce quality human antibodies. The company has several early-to-mid stage candidates in its portfolio.
Agenus’ track record has been mixed so far. The company has surpassed estimates twice in the trailing four quarters and missed the same in two other occasions, bringing the average negative surprise to 5.36%.
Currently, Agenus has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Agenus reported narrower-than-expected loss in the first quarter of 2017. Our consensus called for a loss of 32 cents per share, while the company reported a loss of 18 cents.
Revenue: Revenues, however, missed expectations. Agenus posted revenues of $26.6 million, compared to our consensus estimate of $5.22 million.
Cash and Cash Equivalents: Cash, cash equivalents and short-term investments increased $48 million in this quarter sequentially to $124 million as of Mar 31, 2017.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Agenus (AGEN) Reports Narrower-than-Expected Q1 Loss
Agenus Inc.(AGEN - Free Report) is a Lexington, MA-based development-stage company focused on the discovery and development of checkpoint modulators, vaccines and adjuvants for the treatment of cancer.
The company earns revenues primarily through fees received under collaboration and license agreements, which not only provide it with funds in the form of upfront and milestone payments and future royalties, but also validate the company’s proprietary product platform. In Mar 2017, the company undertook certain restructuring activities in order to cut costs and focus on developing key product candidates.
With no approved product in its portfolio yet, investor focus should remain on pipeline updates by the company. The company has three platform technologies for the development of its candidates – Retrocyte Display, SECANT and phage display – each designed to produce quality human antibodies. The company has several early-to-mid stage candidates in its portfolio.
Agenus’ track record has been mixed so far. The company has surpassed estimates twice in the trailing four quarters and missed the same in two other occasions, bringing the average negative surprise to 5.36%.
Currently, Agenus has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Agenus reported narrower-than-expected loss in the first quarter of 2017. Our consensus called for a loss of 32 cents per share, while the company reported a loss of 18 cents.
Revenue: Revenues, however, missed expectations. Agenus posted revenues of $26.6 million, compared to our consensus estimate of $5.22 million.
Cash and Cash Equivalents: Cash, cash equivalents and short-term investments increased $48 million in this quarter sequentially to $124 million as of Mar 31, 2017.
Agenus Inc. Price and EPS Surprise
Agenus Inc. Price and EPS Surprise | Agenus Inc. Quote
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>